Radioimmunotherapy with α-particle - emitting213Bi-C- functionalized trans-cyclohexyl-diethylenetriaminepentaacetic acid-humanized 3S193 is enhanced by combination with paclitaxel chemotherapy

Clinical Cancer Research

Volumn 13, Issue 18, 2007, Pages

  Kelly, Marcus P ^a   Lee, Fook T ^a   Tahtis, Kiki ^a   Smyth, Fiona E ^a   Brechbiel, Martin W ^b   Scott, Andrew M ^a  

^a AUSTIN HOSPITAL   (Australia)

^b NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BISMUTH 213; HUMAN MONOCLONAL ANTIBODY; HUMAN MONOCLONAL ANTIBODY 3S193; HUMAN MONOCLONAL ANTIBODY 3S193 BI 213; PACLITAXEL; UNCLASSIFIED DRUG;

ALPHA RADIATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; BAGG ALBINO MOUSE; CANCER INHIBITION; CELL STRAIN MCF 7; CONFERENCE PAPER; CONFOCAL MICROSCOPY; CONTROLLED STUDY; CYTOTOXICITY; DRUG EFFICACY; DRUG POTENTIATION; MINIMAL RESIDUAL DISEASE; MOUSE; NONHUMAN; PRIORITY JOURNAL; RADIOIMMUNOTHERAPY; SINGLE DRUG DOSE; SOLID TUMOR; TUMOR VOLUME;

ALPHA PARTICLES; ANIMALS; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BISMUTH; CELL LINE, TUMOR; COMBINED MODALITY THERAPY; FEMALE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; ISOTHIOCYANATES; LEWIS BLOOD-GROUP SYSTEM; MAMMARY NEOPLASMS, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, NUDE; PACLITAXEL; PENTETIC ACID; RADIOIMMUNOTHERAPY; RADIOISOTOPES; SURVIVAL RATE; TISSUE DISTRIBUTION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 34848840131     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-07-1071     Document Type: Conference Paper

References (49)

1. Scott AM, Geleick D, Rubira M, et al. Construction, production, and characterization of humanized anti-Lewis Y monoclonal antibody 3S193 for targeted immunotherapy of solid tumors. Cancer Res 2000;60:3254-61.
2. y-positive human carcinoma cells and xenografts. Clin Cancer Res 2004;10:4538-49.
3. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. In vivo biodistribution of a humanized anti-Lewis Y monoclonal antibody (hu3S193) in MCF-7 xenografted BALB/c nude mice. Cancer Res 2000;60:4804-11.
4. 90Y-radiolabeled anti-Lewis Y humanized monoclonal antibody hu3S193 and paclitaxel combined-modality radioimmunotherapy in a breast cancer model. J Nucl Med 2006;47:716-25.
5. Sharkey RM, Goldenberg DM. Perspectives on cancer therapy with radiolabeled monoclonal antibodies. J Nucl Med 2005;46 Suppl 1:115-27S.
6. Zalutsky MR. Targeted α-particle therapy of microscopic disease: providing a further rationale for clinical investigation. J Nucl Med 2006;47:1238-40.
7. Milenic DE, Garmestani K, Brady ED, et al. Targeting of HER2 antigen for the treatment of disseminated peritoneal disease. Clin Cancer Res 2004;10:7834-41.
8. Mulford DA, Scheinberg DA, Jurcic JG. The promise of targeted α-particle therapy. J Nucl Med 2005;46 Suppl 1:199-204S.
9. Milenic DE, Garmestani K, Brady ED, et al. α-Particle radioimmunotherapy of disseminated peritoneal disease using a (212)Pb-labeled radioimmunoconjugate targeting HER2. Cancer Biother Radiopharm 2005;20:557-68.
10. Couturier O, Supiot S, Degraef-Mougin M, et al. Cancer radioimmunotherapy with α-emitting nuclides. Eur J Nucl Med Mol Imaging 2005;32:601-14.
11. 90Y-labeled CO17-1A Fab′ fragments in a human colonic cancer model. Cancer Res 1999;59:2635-43.
12. 213Bi-rituximab versus external γ irradiation for the treatment of B-CLL patients: relative biological efficacy with respect to apoptosis induction and chromosomal damage. Eur J Nucl Med Mol Imaging 2003;30:1357-64.
13. Zalutsky MR, Pozzi OR. Radioimmunotherapy with α-particle emitting radionuclides. Q J Nucl Med Mol Imaging 2004;48:289-96.
14. Allen BJ, Raja C, Rizvi S, et al. Intralesional targeted α therapy for metastatic melanoma. Cancer Biol Ther 2005;4:1318-24.
15. Jurcic JG. Targeted α particle immunotherapy for myeloid leukemia. Blood 2002;100:1233-9.
16. Nikula TK, McDevitt MR, Finn RD, et al. α-Emitting bismuth cyclohexylbenzyl DTPA constructs of recombinant humanized anti-CD33 antibodies: pharmacokinetics, bioactivity, toxicity and chemistry. J Nucl Med 1999;40:166-76.
17. 213Bi generator system for therapeutic clinical applications: construction and operation. Appl Radiat Isot 1999;50:895-904.
18. DeNardo SJ. Radioimmunodetection and therapy of breast cancer. Semin Nucl Med 2005;35:143-51.
19. 213Bi]J591) for radioimmunotherapy of prostate cancer. Cancer Res 2000;60:6095-100.
20. Smith-Jones PM. Radioimmunotherapy of prostate cancer. Q J Nucl Med Mol Imaging 2004;48:297-304.
21. Yao Z, Zhang M, Garmestani K, et al. Pretargeted α emitting radioimmunotherapy using (213)Bi 1,4,7,10-tetraazacyclododecane-N, N′,N″,N‴′-tetraacetic acid-biotin. Clin Cancer Res 2004;10:3137-46.
22. 213Bi-conjugated monoclonal antibody. Clin Cancer Res 2005;11:7070-4s.
23. Supiot S, Gouard S, Charrier J, et al. Mechanisms of cell sensitization to α radioimmunotherapy by doxorubicin or paclitaxel in multiple myeloma cell lines. Clin Cancer Res 2005;11:7047-52s.
24. Richman CM, DeNardo SJ, O'Donnell RT, et al. High-dose radioimmunotherapy combined with fixed, low-dose paclitaxel in metastatic prostate and breast cancer by using a MUC-1 monoclonal antibody, m170, linked to indium-111/yttrium-90 via a cathepsin cleavable linker with cyclosporine to prevent human anti-mouse antibody. Clin Cancer Res 2005;11:5920-7.
25. Scott AM, Lee F-T, Jones R, et al. A phase I trial of humanized monoclonal antibody A33 in patients with colorectal carcinoma: biodistribution, pharmacokinetics, and quantitative tumor uptake. Clin Cancer Res 2005;11:4810-7.
26. Wu C, Kobayashi H, Sun B, et al. Stereochemical influence on the stability of radio-metal complexes in vivo. Synthesis and evaluation of the four stereoisomers of 2-(p-nitrobenzyl)-trans-CyDTPA. Bioorg Med Chem 1997;5:1925-34.
27. Perera RM, Narita Y, Furnari FB, et al. Treatment of human tumor xenografts with monoclonal antibody 806 in combination with a prototypical epidermal growth factor receptor-specific antibody generates enhanced antitumor activity. Clin Cancer Res 2005;11:6390-9.
28. Rogakou EP, Pilch DR, Orr A H, Ivanova VS, Bonner WM. DNA double-stranded breaks induce histone H2AX phosphorylation on serine 139. J Biol Chem 1998;273:5858-68.
29. DeNardo SJ, Kukis DL, Kroger LA, et al. Synergy of Taxol and radioimmunotherapy with yttrium-90-labeled chimeric L6 antibody: efficacy and toxicity in breast cancer xenografts. Proc Natl Acad Sci U S A 1997;94:4000-4.
30. Clarke K, Lee FT, Brechbiel MW, Smyth FE, Old LJ, Scott AM. Therapeutic efficacy of anti-Lewis(y) humanized 3S193 radioimmunotherapy in a breast cancer model: enhanced activity when combined with taxol chemotherapy. Clin Cancer Res 2000;6:3621-8.
31. Mattes MJ. Radionuclide-antibody conjugates for single-cell cytotoxicity. Cancer 2002;94:1215-23.
32. Elgqvist J, Andersson H, Back T, et al. α-Radioimmunotherapy of intraperitoneally growing OVCAR-3 tumors of variable dimensions: outcome related to measured tumor size and mean absorbed dose. J Nucl Med 2006;47:1342-50.
33. 213Bi-α radioimmunotherapy for multiple myeloma. Clin Cancer Res 1999;5:3165-70s.
34. Bethge WA, Sandmaier BM. Targeted cancer therapy and immunosuppression using radiolabeled monoclonal antibodies. Semin Oncol 2004;31:68-82.
35. Borchardt PE, Yuan RR, Miederer M, McDevitt MR, Scheinberg DA. Targeted actinium-225 in vivo generators for therapy of ovarian cancer. Cancer Res 2003;63:5084-90.
36. Garrigues J. Ley specific antibody with potent antitumor activity is internalized and degraded in lysosomes. Am J Pathol 1993;142:607-22.
37. Yao Z, Garmestani K, Wong KJ, et al. Comparative cellular catabolism and retention of astatine-, bismuth-, and lead-radiolabeled internalizing monoclonal antibody. J Nucl Med 2001;42:1538-44.
38. 213Bi)-labeled-plasminogen activator inhibitor type 2 (α-PAI-2) onhuman breast cancer cells. Breast Cancer Res Treat 2002;71:149-59.
39. Allen BJ, Raja C, Rizvi S, et al. Targeted α therapy for cancer. Phys Med Biol 2004;49:3703-12.
40. Rizvi SM, Allen BJ, Tian Z, Goozee G, Sarkar S. In vitro and preclinical studies of targeted α therapy (TAT) for colorectal cancer. Colorectal Dis 2001;3:345-53.
41. 213Bi- herceptin α-conjugate. Cancer Lett 2004;205:161-71.
42. Li Y, Tian Z, Rizvi SM, Bander NH, Allen BJ. In vitro and preclinical targeted α therapy of human prostate cancer with Bi-213 labeled J591 antibody against the prostate specific membrane antigen. Prostate Cancer Prostatic Dis 2002;5:36-46.
43. Kampf G. Induction of DNAd ouble-strand breaks by ionizing radiation of different quality and their relevance for cell inactivation. Radiobiol Radiother (Berl) 1988;29:631-58.
44. 213Bi-PAI2 conjugate selectively induces apoptosis in PC3 metastatic prostate cancer cell line and shows anti-cancer activity in a xenograft animal model. Br J Cancer 2002;86:1197-203.
45. Leatherbarrow EL, Harper JV, Cucinotta FA, O'Neill P. Induction and quantification of γ-H2AX foci following low and high LET-irradiation. Int J Radiat Biol 2006;82:111-8.
46. 213Bi-labelled- plasminogen activator inhibitor type 2. Br J Cancer 2003;88:944-50.
47. 213Bi-labeled anti-CD74. Nucl Med Biol 2003;30:715-23.
48. Choy H. Combining taxanes with radiation for solid tumors. Int J Cancer 2000;90:113-27.
49. Allen BJ, Rizvi SM, Tian Z. Preclinical targeted α therapy for subcutaneous melanoma. Melanoma Res 2001;11:175- 82.